Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

RPR early access program for Rilutek will treat 10,000 patients worldwide prior to approval.

Executive Summary

RPR PROVIDING RILUTEK TO 10,000 ALS PATIENTS WORLDWIDE in the company's early access program prior to approval of the drug. The program for patients with amyotrophic lateral sclerosis (Lou Gehrig's disease), announced by Rhone-Poulenc Rorer on June 22, will begin by registering patients through July 20. On July 24, over 1,000 patients will be selected to receive initial treatment with Rilutek (riluzole) gratis through a computerized random selection process.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS026425

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel